Home >> Research Area >>Others>>Others>> GSK2194069

GSK2194069

human fatty acid synthase inhibitor CAS# 1332331-08-4

GSK2194069

Catalog No. BCC8053----Order now to get a substantial discount!

Product Name & Size Price Stock
GSK2194069: 5mg $138 In Stock
GSK2194069: 10mg Please Inquire In Stock
GSK2194069: 20mg Please Inquire Please Inquire
GSK2194069: 50mg Please Inquire Please Inquire
GSK2194069: 100mg Please Inquire Please Inquire
GSK2194069: 200mg Please Inquire Please Inquire
GSK2194069: 500mg Please Inquire Please Inquire
GSK2194069: 1000mg Please Inquire Please Inquire
Related Products
  • PP242

    Catalog No.:BCC3682
    CAS No.:1092351-67-1
  • A66

    Catalog No.:BCC3715
    CAS No.:1166227-08-2
  • CAL-101 (Idelalisib, GS-1101)

    Catalog No.:BCC1270
    CAS No.:870281-82-6
  • PIK-294

    Catalog No.:BCC4995
    CAS No.:900185-02-6
  • OSI-027

    Catalog No.:BCC4603
    CAS No.:936890-98-1
  • KU-0063794

    Catalog No.:BCC2484
    CAS No.:938440-64-3

Quality Control of GSK2194069

Number of papers citing our products

Chemical structure

GSK2194069

3D structure

Chemical Properties of GSK2194069

Cas No. 1332331-08-4 SDF Download SDF
PubChem ID 67376285 Appearance Powder
Formula C25H24N4O3 M.Wt 428.48
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 100 mg/mL (233.38 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 4-[4-(1-benzofuran-5-yl)phenyl]-3-[[(3S)-1-(cyclopropanecarbonyl)pyrrolidin-3-yl]methyl]-1H-1,2,4-triazol-5-one
SMILES C1CC1C(=O)N2CCC(C2)CC3=NNC(=O)N3C4=CC=C(C=C4)C5=CC6=C(C=C5)OC=C6
Standard InChIKey AQTPWCUIYUOEMG-INIZCTEOSA-N
Standard InChI InChI=1S/C25H24N4O3/c30-24(18-1-2-18)28-11-9-16(15-28)13-23-26-27-25(31)29(23)21-6-3-17(4-7-21)19-5-8-22-20(14-19)10-12-32-22/h3-8,10,12,14,16,18H,1-2,9,11,13,15H2,(H,27,31)/t16-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of GSK2194069

DescriptionPotent human fatty acid synthase (hFASN) inhibitor (IC50 = 7.7 nM); inhibits hFAS β-ketoacyl reductase activity. Inhibits lipid synthesis and attenuates proliferation of A549 non-small-cell lung cancer cells (EC50 = 15 nM) in vitro.

GSK2194069 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

GSK2194069 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of GSK2194069

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.3338 mL 11.6692 mL 23.3383 mL 46.6766 mL 58.3458 mL
5 mM 0.4668 mL 2.3338 mL 4.6677 mL 9.3353 mL 11.6692 mL
10 mM 0.2334 mL 1.1669 mL 2.3338 mL 4.6677 mL 5.8346 mL
50 mM 0.0467 mL 0.2334 mL 0.4668 mL 0.9335 mL 1.1669 mL
100 mM 0.0233 mL 0.1167 mL 0.2334 mL 0.4668 mL 0.5835 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on GSK2194069

IC50: 7.7 nM

GSK 2194069 is a potent human fatty acid synthase inhibitor.

Human fatty acid synthase (hFAS) is a multifunctional enzyme solely responsible for the de novo synthesis of long chain fatty acids. hFAS is expressed highly in a number of cancers, while with low observed expression in most normal tissues. Though normal tissues get fatty acids from the diet, tumor tissues can rely on de novo fatty acid synthesis, which makes hFAS an attractive metabolic target for cancer treatment.

In vitro: GSK2194069 displayed acceptable solubility and permeability and thus was chosen for further characterization. GSK2194069 had an IC50 of 29 ± 3.2 nM versus hFAS with acetoacetyl-CoA as the substrate but showed little or no inhibition with crotonyl-CoA andβ-hydroxybutyryl-CoA. GSK2194069 was also found not to inhibit the partial activities of the KS domain [1].

In vivo: In those mice dosed with GSK2194069, tumour growth was inhibited. There was no significant weight loss in the GSK2194069 treated group and no adverse effects were observed. The effect of GSK2194069 in decreasing acetate uptake was demonstrated by scintillation detection of C42b xenograft tumours by 56% 2 hours after dosing with GSK2194069. Inhibition of FAS caused by GSK2194069 led to a decrease in acetate signal in all animals [1].

Clinical trial: N/A

References:
[1] Hardwicke MA,Rendina AR,Williams SP,Moore ML,Wang L,Krueger JA,Plant RN,Totoritis RD,Zhang G,Briand J,Burkhart WA,Brown KK, Parrish CA.  A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site. Nat Chem Biol.2014 Sep;10(9):774-9.
[2] Greg Shaw, David Lewis, Joan Boren, Antonio Ramos-Montoya, Robert Bielik, Dmitry Soloviev, Brindle Kevin, Neal David.  509 THERAPEUTIC FATTY ACID SYNTHASE INHIBITION IN PROSTATE CANCER AND THE USE OF 11C-ACETATE TO MONITOR THERAPEUTIC EFFECTS. The Journal of Urology. 2013Volume 189, Issue 4, Supplement, Pagese208–e209

Featured Products
New Products
 

References on GSK2194069

Molecular Pathways: Fatty Acid Synthase.[Pubmed:26519059]

Clin Cancer Res. 2015 Dec 15;21(24):5434-8.

Therapies that target tumor metabolism represent a new horizon in anticancer therapies. In particular, cancer cells are dependent on the generation of lipids, which are essential for cell membrane synthesis, modification of proteins, and localization of many oncogenic signal transduction enzymes. Because fatty acids are the building blocks of these important lipids, fatty acid synthase (FASN) emerges as a unique oncologic target. FASN inhibitors are being studied preclinically and beginning to transition to first-in-human trials. Early generation FASN inhibitors have been studied preclinically but were limited by their pharmacologic properties and side-effect profiles. A new generation of molecules, including GSK2194069, JNJ-54302833, IPI-9119, and TVB-2640, are in development, but only TVB-2640 has moved into the clinic. FASN inhibition, either alone or in combination, holds promise as a novel therapeutic approach for patients with cancer.

A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site.[Pubmed:25086508]

Nat Chem Biol. 2014 Sep;10(9):774-9.

Human fatty acid synthase (hFAS) is a complex, multifunctional enzyme that is solely responsible for the de novo synthesis of long chain fatty acids. hFAS is highly expressed in a number of cancers, with low expression observed in most normal tissues. Although normal tissues tend to obtain fatty acids from the diet, tumor tissues rely on de novo fatty acid synthesis, making hFAS an attractive metabolic target for the treatment of cancer. We describe here the identification of GSK2194069, a potent and specific inhibitor of the beta-ketoacyl reductase (KR) activity of hFAS; the characterization of its enzymatic and cellular mechanism of action; and its inhibition of human tumor cell growth. We also present the design of a new protein construct suitable for crystallography, which resulted in what is to our knowledge the first co-crystal structure of the human KR domain and includes a bound inhibitor.

Description

GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS with an IC50 of 7.7 ± 4.1 nM in an assay detecting released CoA.

Keywords:

GSK2194069,1332331-08-4,Natural Products,Others, buy GSK2194069 , GSK2194069 supplier , purchase GSK2194069 , GSK2194069 cost , GSK2194069 manufacturer , order GSK2194069 , high purity GSK2194069

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: